How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer’s disease? And what on Earth is an “oversubscribed Series A round”?

We discuss all that and more in the latest episode of “The Readout LOUD,” STAT’s biotech podcast. Tune in for a conversation with Dr. Peter Bach of Memorial Sloan Kettering Cancer Center about just how the government should pay for those pricey-but-effective new CAR-T therapies. Then we break down some of the jargon startups employ when they raise money and explain why some of it doesn’t exactly mean what you might think. Also STAT’s Sharon Begley joins us to talk about why the drug industry’s Alzheimer’s pipeline offers so little hope to patients already showing symptoms of the disease, and we embark on a lightning round touching on Gilead Sciences’ changing of the guard, gene therapy’s commercial future, and why good news at the FDA can be bad news on Wall Street.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy